TGFB1 and Miyoshi myopathy: The observation that MM cells demonstrate increased secretion of TGF-b linked to impaired immune surveillance and catabolic bone remodeling [187] led to a phase Ib trial (NCT03143985) of the TGF-b blocker vactosertib and pomalidomide in RRMM.